Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
Recruiting · NCT06889688 · Registry updated 2026-04-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 3 | 2026-04-23 | NCT06889688 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 285 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Changhai Hospital of Shanghai | Shanghai | China | 2 |
| Sun Yat-sen Memorial Hospital | Guangzhou | China | 16 |
| the Affiliated Hospital of Guizhou Medical University | Guiyang | China | 29 |
| The Central Hospital Of Yong Zhou | Yongzhou | China | 1 |
| Wuhan Union Hospital of China | Wuhan | China | 2 |
| Xiangya Hospital of Central South University | Changsha | China | 36 |
| Yichang Central People's Hospital | Yichang | China | 13 |